Drug intelligence / Profile preview

GB232

Development stage: Preclinical
Lead developer: Genor Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

GB232 is a biosimilar to adalimumab (Humira), a monoclonal antibody developed by Genor BioPharma for the treatment of autoimmune diseases. In June 2013, Genor BioPharma licensed GB232 to Biocnd of Korea, granting rights for South Asia, Southeast/Northeast Asia (excluding Greater China), and Russia. Biocnd is responsible for international clinical development and registration in these specified regions. Walvax Biotechnology acquired a majority stake in Genor BioPharma in January 2014, strategically expanding into the monoclonal antibody development sector.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on GB232.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB232.

Explore the full profile